Allison P. Jacob

Zanubrutinib, Obinutuzumab, and Venetoclax in CLL: Long-Term Follow Up, MRD Kinetics, Retreatment, T-Cell Profiling, PKs

Jacob D. Soumerai, Meghan C. Thompson, Ahmet Doǧan, Venkatraman Seshan et autres

Triplet regimens induce high rates of undetectable MRD at ≤10-4 (uMRD4) and appear to prolong progression-free survival (PFS) in treatment-naïve (TN) CLL, but the optimal treatment duration to minimize the risk of neutropenia/infections is unknown. In this phase 2 trial, we evaluated …

us, py (code pays fourni par la source)

Redefining post-CD19 CAR T-cell surveillance with ctdna: Real-world insights from post- axi-cel and liso-cel therapy

Snegha Ananth, Jayasindhu Mallampet, Betty Chang, Neha Agarwal et autres

Abstract Introduction: Circulating tumor DNA (ctDNA)-based measurable residual disease (MRD) assessment is a promising noninvasive biomarker to guide treatment response and surveillance in Large B-cell lymphoma (LBCL). While PET-CT surveillance remains standard of care following anti-CD19 CAR T-cell therapy (CAR19), its limited …

us (code pays fourni par la source)

Disease burden by NGS in bone marrow and peripheral blood samples at baseline and after frontline therapy: Subgroup analysis of the advance randomized multi-center study of carfilzomib, lenalidomide and dexamethasone (KRd) with or without daratumumab (D) in patients with newly diagnosed multiple myeloma (NDMM)

Michael Durante, J Christine Ye, Jens Hillengaß, Douglas W. Sborov et autres

Abstract Introduction: ADVANCE (NCT04268498) is a fully enrolled, ongoing trial for patients with newly diagnosed multiple myeloma (NDMM). Patients were randomly assigned to receive 8 cycles of carfilzomib-lenalidomide-dexamethasone (KRd) with or without daratumumab (D). Patients who were minimal residual disease (MRD) positive …

us (code pays fourni par la source)

Comparative Analysis of ClonoSEQ MRD Testing from Bone Marrow and Circulating Tumor DNA Assessment in Multiple Myeloma

Julia E. Wiedmeier, Mariano Arribas, Heidi Kosiorek, Heidi Simmons et autres

Early peripheral blood and bone marrow MRD as prognostic markers in quadruplet‐treated multiple myeloma without transplant

Benjamin A. Derman, Jennifer H. Cooperrider, Anna Puła, Heidi Simmons et autres

us, pl (code pays fourni par la source)

316 | MULTI‐TARGETED THERAPY WITH VIPOR‐P IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: UPDATED ANALYSIS OF EFFICACY AND MINIMAL RESIDUAL DISEASE

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, J. D. Phelan et autres

Conclusions: ENi at certain locations is a prognostic marker in newly diagnosed PBL.BM was the EN site with the highest prognostic impact.Cases with ENi at any location except for the BM showed an intermediate outcome between patients without ENi and those with …

us (code pays fourni par la source)

45 | MULTI‐TARGETED THERAPY WITH ViPOR IN MANTLE CELL LYMPHOMA (MCL); UPDATED ANALYSIS OF EFFICACY AND MINIMAL RESIDUAL DISEASE (MRD)

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan et autres

þ), including 1 PB(þ), 1 BM(þ), 9 BM/PB(-); 108 ctDNA(-) including 12 BM(þ), 96 PB/BM(-)].With a median follow up of 78 months, median PFS was not reached (NR) neither for the 108 pts with ctDNA(-) at EOI nor for the 105 PB/BM(-).Median …

us (code pays fourni par la source)

427 | MONITORING CIRUCLATING TUMOR DNA IMPROVES EARLY RELAPSE DETECTION AFTER STANDARD OF CARE 2L+ AXI‐CEL IN LBCL: A PROSPECTIVE STUDY

Sachin Ananth, Jayasindhu Mallampet, Betty Chang, Neha Agarwal et autres

PET-CT scans for patient receiving 2Lþ axi-cel.Achieving uMRD as early as Day 14 after 2Lþ axi-cel was strongly correlated with improved PFS.

us (code pays fourni par la source)

Improved Predication of Response and Relapse in Nodal B-Cell Lymphomas with the Use of Ctdna As Compared to Cellular Assays for Measurable Residual Disease

Adam Kidwell, Tyce Kearl, Timothy S. Fenske, Mehdi Hamadani et autres

Introduction Measurable residual disease (MRD) is a clinical prognostic tool utilized in B-cell malignancies to indicate depth of response which in turn correlates with long-term outcomes. Our group previously reported that MRD assessment from cells using clonoSEQ® (Adaptive Biotechnologies) was an effective …

us (code pays fourni par la source)

Circulating Tumor DNA Predicts Time to First Treatment in Previously Untreated Follicular Lymphoma: Analysis from a Prospective Clonal Evolution Study

Rahul Lakhotia, Stefania Pittaluga, James D. Phelan, Allison I. Graeter et autres

Background:Follicular lymphoma (FL) shows marked heterogeneity in clinical course including spontaneous regression and histologic transformation (HT). Watchful waiting (W&W) is routinely employed, but monitoring is not standardized. A subset of pts require treatment early after diagnosis, but biologic basis is unclear. Improved …

us (code pays fourni par la source)

Phase 1/2 Study of Polatuzumab in Combination with Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR-P) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Preliminary Safety, Efficacy, and Molecular Analysis

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan et autres

Background: Relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) pts, especially those who are not cured with CAR-T, have poor outcome. Targeted agents can disrupt key survival pathways in DLBCL, but rarely induce durable responses as monotherapy. We previously showed combination targeted therapy …

us (code pays fourni par la source)

Phase 1b/2 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed/Refractory and Treatment-Naïve Mantle Cell Lymphoma: Preliminary Analysis of Safety, Efficacy, and Minimal Residual Disease

Christopher Melani, Rahul Lakhotia, Stefania Pittaluga, James D. Phelan et autres

Background: Mantle cell lymphoma (MCL) is incurable with standard chemotherapy. Although oral targeted agents are active in MCL, they fail to induce deep responses as monotherapy and are administered chronically. We developed a fixed-duration, multi-agent targeted regimen (ViPOR) and showed it to …

us (code pays fourni par la source)